A cost-effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae

Sexually Transmitted Diseases

Volumn 29, Issue 9, 2002, Pages 542-551

  Gift, Thomas L ^a   Walsh, Cathleen ^a   Haddix, Anne ^a   Irwin, Kathleen L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; DOXYCYCLINE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENE PROBE; GONORRHEA; HEALTH CARE COST; INFECTION RATE; LIGASE CHAIN REACTION; MEDICAL DECISION MAKING; NEISSERIA GONORRHOEAE; NONHUMAN; PELVIC INFLAMMATORY DISEASE; TREATMENT OUTCOME;

EID: 0037008964     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200209000-00009     Document Type: Article

References (67)

1. 1998 Guidelines for treatment of sexually transmitted diseases
2. Pelvic inflammatory disease: Guidelines for prevention and management
3. HIV prevention through early detection and treatment of other sexually transmitted diseases-United States recommendations of the advisory committee for HIV and STD prevention
4. Recommendations for the prevention and management of Chlamydia trachomatis infections
5. Screening for chlamydial infection: Recommendations and rationale
6. Screening for gonorrhea-including ocular prophylaxis in newborns
7. STD treatment guidelines
8. Sexually transmitted diseases treatment guidelines
9. Pelvic inflammatory disease
10. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure
11. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital-tract infections and pelvic inflammatory disease
12. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin
13. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999
14. Cost-effectiveness of combined treatment for endocervical gonorrhea
15. Current methods of laboratory diagnosis of Chlamydia trachomatis infections
16. The neglected health and economic impact of STDs
17. The treatment of pelvic inflammatory disease
18. Detection of Chlamydia trachomatis in fallopian tube tissue in women with postinfectious tubal infertility
19. Atypical pelvic inflammatory disease: Can we identify the clinical predators?
20. Chlamydia trachomatis infections in the United States: What are they costing us?
21. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis
22. Screening women for Chlamydia trachomatis in family planning clinics
23. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial
24. Is the routine pelvic examination needed with the advent of urine-based screening for sexually transmitted diseases?
25. Gonorrhea prevalence and coinfection with chlamydia in women seen in family planning clinics
26. Silent upper genital tract chlamydia infection and disease in women
27. Gonococcal infections in the adult
28. Chlamydia trachomatis infant pneumonitis
29. Chlamydia in the neonate
30. Prospective study of perinatal transmission of Chlamydia trachomatis
31. Chlamydial infections in infants and children
32. Gonococcal diseases in infants and children
33. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis
34. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women
35. Compliance with doxycycline therapy in sexually transmitted diseases clinics
36. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis
37. Chlamydia test monitoring during therapy
38. Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes
39. Azithromycin in the treatment of sexually transmitted disease
40. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women
41. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: The emergence of decreased susceptibility to the fluoroquinolones
42. Oral cefixime versus intramuscular ceftriaxone in patients with uncomplicated gonococcal infections
43. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea
44. Head-to-head comparison of cervical and urine LCR and PCR with a DNA probe test for Chlamydia trachomatis (CT) infection in women
45. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by ligase chain reaction-based assays with clinical specimens from various sites: Implications for diagnostic testing and screening
46. Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in genitourinary specimens from men and women by a coamplification PCR assay
47. Laboratory testing for Neisseria gonorrhoeae by recently introduced nonculture tests: A performance review with clinical and public health considerations
48. Comparisons of cost and accuracy of DNA probe test and culture for the detection of Neisseria gonorrhoeae in patients attending public sexually transmitted disease clinics in Los Angeles County
49. Comparison of ligase chain reaction and culture for detection of Neisseria gonorrhoeae in genital and extragenital specimens
50. Cost of and payment source for pelvic inflammatory disease trends and projections
51. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women
52. Use of cell culture and a rapid diagnostic assay for Chlamydia trachomatis screening
53. Completeness of and duration of time before treatment after screening women for Chlamydia trachomatis infections
54. Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic
55. Patterns of Chlamydia trachomatis testing and follow-up at a university hospital medical center
56. Comparison of performance and cost-effectiveness of direct fluorescent-antibody, ligase chain reaction, and PCR assays for verification of chlamydial enzyme immunoassay results for populations with a low to moderate prevalence of Chlamydia trachomatis infection
57. Treating chlamydial infection: Compliance versus cost
58. Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis
59. The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic
60. The negative side of cost-effectiveness analysis